Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

FDA Panel to Consider Pfizer's Second-Line HIV Drug

February 9, 2007

On April 24, the Food and Drug Administration's antiviral drugs advisory panel will review maraviroc, a new CCR5 antagonist candidate made by Pfizer. The agency said Thursday its panel will evaluate the twice-daily pill's safety and efficacy data.

CCR5 antagonists block HIV from entering white blood cells through a pathway found in most patients with the virus. Pfizer will administer the drug along with a test made by Monogram Biosciences Inc. that evaluates whether patients are likely to respond to the treatment.

Rival drug companies are also developing second-line HIV drugs, these are typically for use by highly treatment-experienced patients with drug-resistant virus. However, UK-based GlaxoSmithKline stopped development of its candidate aplaviroc in 2005 after some patients developed signs of liver damage. At Schering-Plough Corp., mid-stage trials of a new second-line candidate are continuing, though the company reported some patients developed lymphomas.

Advertisement
Pfizer reports its trials of maraviroc have gone smoothly so far.

Back to other news for February 9, 2007

Adapted from:
Associated Press
02.08.2007; Matthew Perrone


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
More News and Research on Maraviroc (Selzentry, Celsentri)

Tools
 

Advertisement